NASDAQ:NTRP - Neurotrope Stock Price, Forecast & News

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

Neurotrope Inc (NASDAQ:NTRP) released its earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. View Neurotrope's Earnings History.

Neurotrope is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Neurotrope.

2 Wall Street analysts have issued 12 month price objectives for Neurotrope's shares. Their forecasts range from $1.00 to $1.00. On average, they anticipate Neurotrope's stock price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 13.8%. View Analyst Price Targets for Neurotrope.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.

News headlines about NTRP stock have trended very negative this week, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neurotrope earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Neurotrope.

Some companies that are related to Neurotrope include NewLink Genetics (NLNK), Soligenix (SNGX), SCYNEXIS (SCYX), Aclaris Therapeutics (ACRS), Alpine Immune Sciences (ALPN), DiaMedica Therapeutics (DMAC), American Brivision (Holding) (ABVC), Processa Pharmaceuticals (PCSA), Leap Therapeutics (LPTX), Bellicum Pharmaceuticals (BLCM), Aridis Pharmaceuticals (ARDS), Q BioMed (QBIO), Acasti Pharma (ACST), IntelGenx Technologies (IGXT) and resTORbio (TORC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Pieris Pharmaceuticals (PIRS), Canopy Growth (CGC), Intel (INTC), Iovance Biotherapeutics (IOVA), Adamis Pharmaceuticals (ADMP) and Innovate Biopharmaceuticals (INNT).

Neurotrope's stock is owned by a number of of institutional and retail investors. Top institutional investors include Cannell Peter B & Co. Inc. (1.03%). View Institutional Ownership Trends for Neurotrope.

NTRP stock was sold by a variety of institutional investors in the last quarter, including Cannell Peter B & Co. Inc.. View Insider Buying and Selling for Neurotrope.

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NTRP stock can currently be purchased for approximately $1.16.

Neurotrope has a market capitalization of $15.16 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.

The official website for Neurotrope is http://www.neurotropebioscience.com/.

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]